Effect of Folic Acid on Endothelial and Baroreceptor Function in Patients With Heart Failure
Primary Purpose
Heart Failure
Status
Terminated
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
folic acid 5mg/day
Sponsored by
About this trial
This is an interventional treatment trial for Heart Failure focused on measuring folic acid, endothelial function, baroreceptor function, heart failure
Eligibility Criteria
Inclusion Criteria:
- Heart failure (min. NYHA ll, LVEF <50%)
- Not smokers
- Written informed consent
Exclusion Criteria:
- Unstable heart failure
- Smoking
- Unstabile Angina Pectoris
- Endocrinologic disease such as Diabetes mellitus, Hypo- und Hyperthyroidism
- Alcohol abuse
- Epilepsia
- Treatment with folic acid antaponists Trimethoprim, Pyrimethamin, Methotrexat..
- Participation to one other clinical Study within 1 Month
Sites / Locations
Outcomes
Primary Outcome Measures
change in endothelial function
change in baroreceptor function
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00491907
Brief Title
Effect of Folic Acid on Endothelial and Baroreceptor Function in Patients With Heart Failure
Official Title
Effect of Folic Acid on Endothelial and Baroreceptor Function in Patients With Heart Failure
Study Type
Interventional
2. Study Status
Record Verification Date
October 2007
Overall Recruitment Status
Terminated
Why Stopped
recruitment is finished
Study Start Date
October 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
May 2007 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
University of Zurich
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The randomized, double-blind, placebo-controlled study aim to evaluate the effect of 1-month therapy with folic acid (5 mg/day) on endothelial function and baroreceptor function in patients with heart failure.
Endothelial function will be studied non-invasively with flow-mediated dilation while for eveluating baroreceptor function sympathetic nervous system activity will be measured directly with microneurography in baseline condition and during infusion of sodium-nitroprusside.
Detailed Description
Endothelial and baroreceptor function are impaired in patients with heart failure.
Impaired baroreflex control of the heart and peripheral circulation and endothelial dysfunction are thought to play an important pathophysiological role in chronic heart failure and confers a poor prognosis.
In patients with essential hypertension we demonstrated an improvement in baroreceptor function after treatment with folic acid.
Therefore, the aim of the present randomized, double-blind, placebo-controlled study was to evaluate endothelial function and baroreceptor function in patients with heart failure before and after 1-month therapy with folic acid (5 mg) or placebo.
Endothelial function will be assessed with novel high-resolution ultrasound devices, which allows to investigate endothelial function in vivo. This method makes use of the property of the endothelium to release nitric oxide in response to shear stress and increased flow as previously described. Endothelium-dependent flow-mediated dilation (FMD) and endothelium-independent glycerol trinitrate (GTN) (0.4 mg sublingual, Nitrolingual Spray, Pohl-Boskamp, Germany)-induced vasodilation of the brachial artery will be assessed by a high-resolution ultrasound vessel wall tracking device with a 10 MHz linear array transducer . FMD of the brachial artery is induced by release of a wrist cuff inflated 50 mmHg above systolic pressure for 5 minutes. After sublingual GTN application, used as endothelium-independent stimulus, the diameter will be recorded every 30 seconds for 6 minutes.
Multifiber recordings of muscle sympathetic nerve activity will be obtained from the peroneal nerve posterior to the fibular head with tungsten microelectrodes. The sympathetic nervous activity will be measured continuously together with ECG, respiration rate and blood pressure. Baroreceptor modulation of muscle sympathetic nerve activity and heart rate would be assessed by intravenous infusion of sodium nitroprusside.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure
Keywords
folic acid, endothelial function, baroreceptor function, heart failure
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
folic acid 5mg/day
Primary Outcome Measure Information:
Title
change in endothelial function
Time Frame
1 month
Title
change in baroreceptor function
Time Frame
1 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Heart failure (min. NYHA ll, LVEF <50%)
Not smokers
Written informed consent
Exclusion Criteria:
Unstable heart failure
Smoking
Unstabile Angina Pectoris
Endocrinologic disease such as Diabetes mellitus, Hypo- und Hyperthyroidism
Alcohol abuse
Epilepsia
Treatment with folic acid antaponists Trimethoprim, Pyrimethamin, Methotrexat..
Participation to one other clinical Study within 1 Month
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Georg Noll, MD
Organizational Affiliation
Cardiovascular Center, University Hospital Zurich, Zurich, Switzerland
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Effect of Folic Acid on Endothelial and Baroreceptor Function in Patients With Heart Failure
We'll reach out to this number within 24 hrs